MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics.
MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics.
复制标题
DOI：
10.1002/cam4.775
复制
发表时间：
2016-08
期刊：
影响因子：
4
通讯作者：
Kumar D
中科院分区：
文献类型：
--
作者：
Shea A;Harish V;Afzal Z;Chijioke J;Kedir H;Dusmatova S;Roy A;Ramalinga M;Harris B;Blancato J;Verma M;Kumar D
多形性胶质母细胞瘤（GBM）是成人脑部最常见和最致命的癌症，仍然无法治愈，中位生存时间仅为15个月。为了确定GBM诊断和治疗的新靶点，最近的研究集中在GBM亚型的分子表型上。由于microRNAs在正常发育和病理条件（如癌症）中的调节能力，这导致了对microRNAs （miRNAs）的兴趣日益增加。mirna具有广泛的靶标，允许它们调节许多对癌症进展至关重要的途径，包括增殖、细胞死亡、转移、血管生成和耐药性。这篇综述探讨了我们目前对差异调节和病理参与GBM的miRNA的理解，以及基于miRNA的治疗方法的现状。随着miRNA在GBM中的作用越来越被了解，以及新的给药方法的开发和优化，基于miRNA的治疗可能为癌症治疗提供关键的一步。
Glioblastoma multiforme (GBM) is the most common and lethal cancer of the adult brain, remaining incurable with a median survival time of only 15 months. In an effort to identify new targets for GBM diagnostics and therapeutics, recent studies have focused on molecular phenotyping of GBM subtypes. This has resulted in mounting interest in microRNAs (miRNAs) due to their regulatory capacities in both normal development and in pathological conditions such as cancer. miRNAs have a wide range of targets, allowing them to modulate many pathways critical to cancer progression, including proliferation, cell death, metastasis, angiogenesis, and drug resistance. This review explores our current understanding of miRNAs that are differentially modulated and pathologically involved in GBM as well as the current state of miRNA‐based therapeutics. As the role of miRNAs in GBM becomes more well understood and novel delivery methods are developed and optimized, miRNA‐based therapies could provide a critical step forward in cancer treatment.